• News
  • Company News
  • Industry News
  • Latest Announcement
  • Culture

  • Cultural Concept
  • Staff Presence
  • Social Responsibility
  • Join Us

  • Join Us
  • Talent Concept
  • Well-paid Job
  • Contact Us

  • Products
  • SARS-COV-2 VACCINE(VERO CELL), INACTIVATED
  • Recombinant Hepatitis B Vaccine (10μg/20μg/60μg)
  • 23-Valent Pneumococcal Polysaccharide Vaccine
  • Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
  • Haemophilus Influenzae Type b Conjugate Vaccine
  • Measles and Rubella Combined Vaccine ,Live
  • R&D Vaccine

  • 13-Valent Pneumococcal Conjugate Vaccine
  • Rabies vaccine (human diploid cell) for human use, Freeze-dried
  • Inactivated Poliomyelitis Vaccine, Sabin Strains
  • Hib Conjugate Vaccine, Freeze-dried
  • Service
  • R&D
  • International
  • GMP Certificate
  • Products Certificate
  • Overseas Market

  • Investor Relations
  • Company Announcements
  • Shareholder Returns
  • Stock quotation

  • Investor Online
  • Investors Contact
  • News
  • 中文版

    Since its establishment in 1992, BioKangtai has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks, and has possessed core technologies such as polyvalent vaccines, genetic engineering vaccines and other new technology R&D and industrialization core competitiveness. The company has 8 research and development carriers such as academician expert workstations, and its products cover more than 3,130 provinces, municipalities and autonomous regions. Among them, the self-developed cell-free whitebait b-type Haemophilus influenzae combined vaccine is the domestically-innovated “quadruple vaccine”, and the 60-microg hepatitis B vaccine specifically targeting unresponsive people has the “National Key New Product” title.

    30+Years

    Development History

    90000

    Production base

    30+Item

    In vaccine research

    400+

    Research staff

    8+

    Available vaccine varieties

    Company news Recombinant COVID-19 Vaccine (Adenovirus Vector) licensed for manufacturing
    Recombinant COVID-19 Vaccine (Adenovirus Vector) licensed for manufacturing
    2021-09-06

    Biokangtai:RecombinantCOVID-19 Vaccine(AdenovirusVector)licensed formanufacturing,whichactively promotesvaccineexportandimproves vaccineaccessibility

    More
    Industry news China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
    China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
    2021-02-09

    China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines

    More
    News
  • Recombinant COVID-19 Vaccine (Adenovirus Vector) licensed for manufacturing

    Biokangtai:RecombinantCOVID-19 Vaccine(AdenovirusVector)licensed formanufacturing,whichactively promotesvaccineexportandimproves vaccineaccessibility

    2021-09-06
  • Shenzhen Kangtai says vaccine effective against Delta variant

    Shenzhen Kangtai says vaccine effective against Delta variant

    2021-08-04
  • BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines

    BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines

    2021-08-02
  • Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia

    Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia

    2021-06-23